Gilead nears deal to buy Immunomedics for more than $20 billion: Report

(Reuters) - Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter. A deal for Immunomedics, which last month reported positive data from a late-stage study for its breast-cancer drug, could be announced Monday if not sooner, the Journal said https://www. Gilead and Immunomedics.....

This article is no longer available in our repository.

There could be multiple reasons for this.